Intellia Therapeutics (NTLA) Assets Average (2016 - 2026)

Intellia Therapeutics (NTLA) has 11 years of Assets Average data on file, last reported at $800.5 million in Q1 2026.

• On a quarterly basis, Assets Average fell 26.47% year-over-year to $800.5 million in Q1 2026; TTM through Mar 2026 was $800.5 million, a 26.47% decrease from a year earlier, with the FY2025 full-year figure at $1.0 billion, down 18.41% from the prior year.
• Assets Average for Q1 2026 stood at $800.5 million, down from $883.7 million in the prior quarter.
• Over the last five years, Assets Average for NTLA reached as high as $1.5 billion in Q1 2023 and fell as low as $800.5 million in Q1 2026.
• Historically, Assets Average has averaged $1.2 billion across 5 years, with a median of $1.2 billion in 2024.
• Across the five-year window, Assets Average jumped 79.24% in 2022 and declined 26.47% in 2026, its largest moves.
• Year by year, Assets Average stood at $1.3 billion in 2022, then decreased by 2.31% to $1.3 billion in 2023, then fell by 7.07% to $1.2 billion in 2024, then fell by 25.25% to $883.7 million in 2025, then fell by 9.42% to $800.5 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $800.5 million in Q1 2026, $883.7 million in Q4 2025, and $912.1 million in Q3 2025.